FASN
ENSG00000169710
Target class
Enzyme
Chromosome
17
- Chemical probe available
- Yes
- Target name
- FASN
- Gene name
- Fatty acid synthase
- Gene symbol
- FASN
- Protein name
- Fatty acid synthase (EC 2.3.1.85) (Type I fatty acid synthase) [Includes: [Acyl-carrier-protein] S-acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-[acyl-carrier-protein] reductase (EC 1.1.1.100); 3-hydroxyacyl-[acyl-carrier-protein] dehydratase (EC 4.2.1.59); Enoyl-[acyl-carrier-protein] reductase (EC 1.3.1.39); Acyl-[acyl-carrier-protein] hydrolase (EC 3.1.2.14)]
- FAS
- SDR27X1
- Gene biotype
- Protein coding
- Gene family
- Short chain dehydrogenase/reductase superfamily|7BS orphan methyltransferases
- Target class
- Enzyme
- Target type
- Human gene
- Tissues expressed in
- 54
- Protein localisation evidence grade
- Enhanced
- Highest tissue expression
- 374.98
- Tissue specificity (Gini)
- 0.474
- Tissue specificity (tau)
- 0.843
- KEGG gene identifiers
- hsa:2194
- Protein interaction confidence
- 0.830346
- Protein interaction partners
- 78
- R-HSA-163765
- R-HSA-199220
- R-HSA-2426168
- R-HSA-75105
- R-HSA-9029558
- R-HSA-9918481
- R-HSA-9918487
- End position
- 82098294
- Start position
- 82078338
- Chromosome
- 17
- Strand
- Reverse
- Cytoplasm . Melanosome . Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV.
- Cytosol
- Plasma membrane
Publication evidence
- PubMed 17081065
- Tissue specificity (tau)
- 0.843366
- Expression inequality (Gini)
- 0.473718
Expression in transcripts per million
- Adipose - Subcutaneous
- 374.98
- Breast - Mammary Tissue
- 291.74
- Adipose - Visceral (Omentum)
- 290.36
- Brain - Cerebellum
- 165.08
- Brain - Cerebellar Hemisphere
- 131.02
Expression in transcripts per million
- Adipose - Subcutaneous374.98
- Breast - Mammary Tissue291.74
- Adipose - Visceral (Omentum)290.36
- Brain - Cerebellum165.08
- Brain - Cerebellar Hemisphere131.02
- Skin - Not Sun Exposed (Suprapubic)127.21
- Skin - Sun Exposed (Lower leg)118.28
- Prostate103.18
- Pituitary99.08
- Esophagus - Mucosa96.77
- Cells - EBV-transformed lymphocytes86.74
- Liver81.47
- Nerve - Tibial80
- Cells - Cultured fibroblasts74.32
- Lung73.4
- Brain - Cortex70.04
- Stomach62.89
- Vagina59.35
- Minor Salivary Gland56.57
- Brain - Frontal Cortex (BA9)55.64
- Brain - Spinal cord (cervical c-1)48.79
- Bladder48.65
- Brain - Anterior cingulate cortex (BA24)46.19
- Artery - Coronary46.1
- Thyroid40.3
And 29 more, listed on the interactive page.
- GO:0001649
- GO:0006631
- GO:0044788
- GO:0046949
- GO:0005737
- GO:0005829
- GO:0005886
- GO:0016020
- GO:0070062
- GO:0003723
- GO:0004312
- GO:0004313
- GO:0004315
- GO:0004316
- GO:0005515
- GO:0019171
- GO:0045296
- GO:0141148
Increased, Liver Steatosis
Effects
- Activation/Increase/Upregulation
Studies
- cell-based
Evidence sourceN/A, Liver Steatosis
Effects
- Activation/Increase/Upregulation
Studies
- cell-based
Evidence source
regulation of transcription factor activity
- cell-based: LTEA_HepaRG_FASNis one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.
- cell-based: LTEA_HepaRG_FASNis one of 100 assay component(s) measured in the LTEA HepaRG cell culture assay. It is a marker of Steatosis.
Biological samples
- HepaRG, cell line
Evidence source
Related records
Trials (77)
- A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants
- A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss
- A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis
- A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH
- A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- A Pilot Study of the Efficacy of Alli in the Management of Pre-operative Weight Loss Required for Bariatric Surgery.
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America
- A Study of Xenical (Orlistat) in Overweight and Obese Adolescents
- A Study to Assess the Pharmacologic Equivalence of Two Orlistat Dosage Forms
- A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris
- A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris
- A Trial With EMP16 in Preparation for Late Phase Studies
- Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder
- Aggressive Treatment of Metabolic Syndrome in Patients Receiving Clozapine for Schizophrenia
- An RCT of Metformin Vs Orlistat in Obese Anovulatory Women
- Anti-obesity Effects of Dandelion (Taraxacum Officinale L.)
- Ascending Single-dose Study to Evaluate TVB-2640 in Chinese Healthy Subjects
- Assess the Additional Weight Loss Effect of Orlistat Used in Combination With Sibutramine
- Combinatorial Therapy for Peristent Type 2 Diabetes After Gastric Banding
Drugs (2)
- Denifanstat
- Orlistat